Bulletin
Investor Alert

London Markets Open in:

Intra-Cellular Therapies Inc.

NAS: ITCI

GO
/marketstate/country/us

After Hours

/zigman2/quotes/209441868/composite

$

48.39

Change

+0.51 +1.07%

Volume

Volume 29,006

Mar 27, 2023, 7:58 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/209441868/composite

Previous close

$ 46.73

$ 47.88

Change

+1.15 +2.46%

Day low

Day high

$46.98

$48.22

Open
Open: 47.26

52 week low

52 week high

$42.01

$66.00

Open

Market cap

$4.45B

Average volume

703,787

P/E ratio

N/A

Rev. per Employee

$446,192

EPS

-2.73

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/itci

MarketWatch News on ITCI

  1. Thematic ETFs Look Tempting. Just Say No.

    5:01 p.m. Dec. 12, 2022

    - Barron's Online

  2. Intra-Cellular Therapies started at buy with $74 stock price target at Mizuho

    7:06 a.m. July 7, 2022

    - Tomi Kilgore

  3. Intra-Cellular Therapies started at buy with $75 stock price target at UBS

    10:52 a.m. June 14, 2022

    - Tomi Kilgore

  4. The FDA Is About to Make Some Major Drug Decisions

    2:51 p.m. Oct. 16, 2021

    - Barron's Online

  5. Intra-Cellular Therapies downgraded to neutral from overweight at J.P. Morgan

    8:54 a.m. Jan. 31, 2020

    - Tomi Kilgore

  6. Intra-Cellular Therapies stock price target raised to $65 vs. $29 at Canaccord

    11:48 a.m. Dec. 24, 2019

    - Ciara Linnane

  7. Intra-Cellular Therapies reiterated as buy at Canaccord

    11:48 a.m. Dec. 24, 2019

    - Ciara Linnane

  8. Intra-Cellular Therapies gets FDA approval for schizophrenia treatment

    8:14 a.m. Dec. 23, 2019

    - Ciara Linnane

  9. Intra-Cellular Therapies stock soars 42% premarket

    8:14 a.m. Dec. 23, 2019

    - Ciara Linnane

  10. Intra-Cellular Therapies shares slide 7% after resuming trade following halt.

    7:36 a.m. July 8, 2019

    - Ciara Linnane

  11. Intra-Cellular announces positive results in late-stage trial of treatment for bipolar depression

    7:05 a.m. July 8, 2019

    - Ciara Linnane

  12. Intra-Cellular Therapies and Sol-Gel Technologies halted for news pending

    6:58 a.m. July 8, 2019

    - Ciara Linnane

  13. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/itci

Other News on ITCI

  1. 10-K: INTRA-CELLULAR THERAPIES, INC.

    8:51 a.m. March 1, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. Top 5 3rd Quarter Trades of GW&K Investment Management, LLC

    3:00 p.m. Nov. 9, 2022

    - GuruFocus.com

  3. Intra-Cellular Therapies Q3 2022 Earnings Preview

    1:39 p.m. Nov. 2, 2022

    - Seeking Alpha

  4. Lisanti Capital Growth, LLC Buys 2, Sells 3 in 3rd Quarter

    9:00 a.m. Nov. 2, 2022

    - GuruFocus.com

  5. Intra-Cellular Therapies: What Lies Ahead

    7:45 p.m. Sept. 20, 2022

    - Seeking Alpha

  6. Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

    1:31 p.m. Sept. 16, 2022

    - Seeking Alpha

  7. Warning: ITCI is at high risk of performing badly

    4:51 a.m. Sept. 9, 2022

    - Seeking Alpha

  8. Loading more headlines...
/news/pressrelease/company/us/itci

Press Releases on ITCI

  1. What Stocks To Buy This Week? 4 Biotech Stocks To Know

    11:20 a.m. May 15, 2022

    - StockMarket.com

  2. Loading more headlines...

Rates »

Link to MarketWatch's Slice.